Published on The Nathan Kline Institute for Psychiatric Research (https://www.nki.rfmh.org)

Home > A Phase II Multicenter, Randomized, Double-Blind, 12-Week Treatment, 3-Arm, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of RO7017773 in Participants Aged 15 to 45 Years with Autism Spectrum Disorder (ASD)

A Phase II Multicenter, Randomized, Double-Blind, 12-Week Treatment, 3-Arm, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of RO7017773 in Participants Aged 15 to 45 Years with Autism Spectrum Disorder (ASD) [1]

The primary objective of this study is to evaluate the effectiveness and safety of RO7017773, a new medication, compared with placebo in the improvement of symptoms of ASD.

Study Length: 
Approximately 5.5 months
Disorder/Condition: 
Autism
Inclusion Criteria: 

Males and Females, ages 15-45 with ASD

Study Title (brief): 
A Phase II Multicenter, Randomized, Double-Blind, 12-Week Treatment, 3-Arm, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of RO7017773 in Participants Aged 15 to 45 Years with Autism Spectrum Disorder (ASD)
Study Description (brief): 

The primary objective of this study is to evaluate the effectiveness and safety of RO7017773, a new medication, compared with placebo in the improvement of symptoms of ASD.

Study Contact: 

Clinical Evaluation Center at 845-398-2184 or vrp@nki.rfmh.org [2]

Study Location: 
Nathan Kline Institute, Orangeburg, NY

Source URL:https://www.nki.rfmh.org/content/phase-ii-multicenter-randomized-double-blind-12-week-treatment-3-arm-parallel-group-placebo

Links
[1] https://www.nki.rfmh.org/content/phase-ii-multicenter-randomized-double-blind-12-week-treatment-3-arm-parallel-group-placebo [2] mailto:vrp@nki.rfmh.org